Company / R&D Expense
UroGen Pharma Ltd. R&D Expense History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$67.1M
FY2025
5-year range
$45.6M / $67.1M
FY2021-FY2025
Trend
+47.1%
vs FY2024
Sector context
#168 of 210
Health Care
What the data says
UroGen Pharma Ltd.'s r&d expense of $67M is lower than 80% of companies in the Health Care sector (FY2025). R&D Expense has fluctuated over the past 9 years, ranging from $19M in FY2019 to $67M in FY2025.
Based on SEC 10-K filings.
$67M in FY2025 with a 5-year CAGR of +6.4%.
Improved from $53M to $67M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +12.1%
- 5-Year CAGR
- +6.4%
- 10-Year CAGR
- -
Sector benchmark
Bottom 20% in Health CareTop 80% of 210This company $67.1M Sector average $644.1M
▼
-89.6% below sector average
Key checks
Key Insights
- 5-year CAGR of +6.4%, indicating consistent growth.
- In FY2025, r&d expense increased 47.1% year-over-year.
- Ranks #168 out of 210 companies in the Health Care sector.
- Lowest r&d expense in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.09 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $67.1M | +47.1% |
| FY2024 | $45.6M | -13.8% |
| FY2023 | $52.9M | +11.0% |
| FY2022 | $47.6M | +0.0% |
| FY2021 | $47.6M | -3.4% |
| FY2020 | $49.3M | +163.7% |
| FY2019 | $18.7M | -49.4% |
| FY2018 | $36.9M | +97.5% |
| FY2017 | $18.7M | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026